



ASX Announcement
18 Sep 2023

emyria

A clinical stage biotech informed by patient experience.
Tackling unmet needs in neuroscience and mental health.

Prospectus and Application Forms made available to Eligible Shareholders

Emyria Limited (ASX: EMD) (**Emyria** or the **Company**) confirms that the Prospectus and Application Form in connection with the non-renounceable entitlement offer (**Entitlement Offer**), as announced to ASX on 6 September 2023, was made available to eligible shareholders today.

The Entitlement Offer opens today, 18 September 2023, and is expected to close at 5.00pm (AWST) on 28 September 2023 (unless extended). Application monies must be received as cleared funds prior to this time, in accordance with the terms of the Prospectus and Application Form.

For all enquiries concerning the Entitlement Offer, please contact the Company by telephone on +61 (08) 6559 2800 or email on info@emyria.com. For all general shareholder enquiries, please contact the Company's Share Registry, Automic Pty Ltd, on +1300 288 664.

You should also consult your stockbroker, solicitor, accountant or other suitably qualified professional adviser to evaluate whether or not to participate in the Entitlement Offer.

This release has been approved by the Board of Emyria.